BAY-293, an SOS1 inhibitor exhibits synergistic activity when combined with ARS-1620 in KRASG12C mutant CRC cancer cell lines proving that targeting the inactive GDP-bound form is a promising approach for generating anti-RAS therapeutics. This evidence concerns the gene SOS1 and cancer.